- Home
- EDU vs ORKA Comparison
EDU vs ORKA Comparison
Compare EDU & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | ORKA |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.1B |
| IPO Year | 2006 | 1997 |
Fundamental Metrics
Financial Performance| Metric | EDU | ORKA |
|---|---|---|
| Price | $58.95 | $91.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $62.80 | ★ $92.50 |
| AVG Volume (30 Days) | 643.5K | ★ 761.4K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.83 | N/A |
| Revenue Next Year | $11.16 | N/A |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.25 | $14.67 |
| 52 Week High | $64.97 | $115.52 |
Technical Indicators
Market Signals| Indicator | EDU | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 40.35 |
| Support Level | $58.45 | $82.34 |
| Resistance Level | $59.71 | $95.02 |
| Average True Range (ATR) | 1.45 | 5.35 |
| MACD | 0.14 | -2.60 |
| Stochastic Oscillator | 92.23 | 20.19 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in livestreaming e-commerce.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.